Skip to main content
Livermore
Livermore
ZHEN

Ensign Peak Advisors, Inc

SEC CIK
0001454984
Latest filing
Aug 14, 2026

APLS holding history

Apellis Pharmaceuticals, Inc. in every 13F filed by Ensign Peak Advisors, Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

APLS overviewAll 13F holders of APLSFull Q2 2026 holdings

Shares (Q2 2026)
0
Sold out in Q2 2026
Value
$0
% of portfolio
0.0%
Quarters held
21
Since Q1 2021
Holdings of APLS by Ensign Peak Advisors, Inc, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20260$00.0%−4,747−100.0%Sold outHolders
Q1 20264,747$191.0K<0.1%00.0%UnchangedHolders
Q4 20254,747$119.2K<0.1%−11,800−71.3%ReducedHolders
Q3 202516,547$374.5K<0.1%−12,850−43.7%ReducedHolders
Q2 202529,397$508.9K<0.1%00.0%UnchangedHolders
Q1 202529,397$642.9K<0.1%−49,700−62.8%ReducedHolders
Q4 202479,097$2.52M<0.1%−1,900−2.3%ReducedHolders
Q3 202480,997$2.34M<0.1%−2,000−2.4%ReducedHolders
Q2 202482,997$3.18M<0.1%−177,277−68.1%ReducedHolders
Q1 2024260,274$15.3M<0.1%+14,708+6.0%AddedHolders
Q4 2023245,566$14.7M<0.1%+60,000+32.3%AddedHolders
Q3 2023185,566$7.06M<0.1%+154,686+500.9%AddedHolders
Q2 202330,880$2.81M<0.1%+950+3.2%AddedHolders
Q1 202329,930$1.97M<0.1%−133,500−81.7%ReducedHolders
Q4 2022163,430$8.45M<0.1%+141,100+631.9%AddedHolders
Q3 202222,330$1.52M<0.1%−117,829−84.1%ReducedHolders
Q2 2022140,159$6.34M<0.1%+99,979+248.8%AddedHolders
Q1 202240,180$2.04M<0.1%−45,409−53.1%ReducedHolders
Q4 202185,589$4.05M<0.1%+82,647+2,809.2%AddedHolders
Q3 20212,942$97.0K<0.1%−43,821−93.7%ReducedHolders
Q2 202146,763$2.96M<0.1%+4,062+9.5%AddedHolders
Q1 202142,701$1.83M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.